Information Provided By: 
Fly News Breaks for June 28, 2019
GERN
Jun 28, 2019 | 08:04 EDT
B. Riley FBR analyst George Zavoico raised his price target for Geron to $4.50 from $3.25 after the company recently presented new results from its two trials of imetelstat in two different blood cancers. The results provide "strong evidence" of safety and efficacy that is "markedly superior" to current standard of care, Zavoico tells investors in a research note. He keeps a Buy rating on Geron.
News For GERN From the Last 2 Days
There are no results for your query GERN
